In product formulation Dr Falk Pharma has special competence in the development of topical delivery systems for diseases of the intestinal tract, which has resulted in a range of patents and approvals.
The project management team in clinical research is highly experienced in the organisation of multi-centre studies required for approval, especially for inflammatory bowel diseases and certain liver diseases. An international network of clinicians has been established over many years, which allows even large multi-centre studies to be carried out rapidly and successfully.
Close co-operation between the Research and Regulatory Affairs departments forms the basis of the high quality of documentation needed to meet the requirements of the regulatory authorities today. Our own experience with the various European regulatory and approval procedures underlies the success of our regulatory team.
As well as new substances for the treatment of inflammatory bowel diseases, further development of already marketed substances are at the forefront of our development activities. New areas of application are also being explored for the drugs currently in use. Approximately 15% of our turnover is invested in R&D.
The drugs are produced in co-operation with other companies and strict controls are applicable in accordance with national and international pharmaceutical manufacturing regulations.